dromlakhani Avoid spontaneous GH testing for GHD diagnosis
STEP 1 — Gather Information
Confirm that the individual is a childhood cancer survivor being evaluated for growth hormone deficiency and that spontaneous GH secretion sampling (e.g., 12‑hour overnight) is being considered. Action: If confirmed, proceed to Step 2; otherwise, employ standard provocative testing per guideline 2.3.
STEP 2 — Rule In / Rule Out
Is the patient a childhood cancer survivor with suspected GHD?
- Yes → Proceed to Step 3 (spontaneous GH sampling not recommended)
- No → Use standard GHD evaluation for non‑cancer population (outside scope) Action: Follow the branch indicated.
STEP 3 — Classify or Stratify
Classify the patient's risk based on radiation exposure: hypothalamic–pituitary axis RT ≥18 Gy increases GHD risk; however, spontaneous GH sampling remains unreliable regardless of dose. Action: Regardless of radiation dose, classify spontaneous GH sampling as inappropriate for GHD diagnosis.
STEP 4 — Decide
Decide to avoid spontaneous GH sampling and instead use a validated provocative test (e.g., insulin tolerance test, glucagon, or GHRH‑arginine) per guideline 2.3. Action: Order appropriate provocative testing; do not order 12‑hour overnight GH sampling.
Clinical Guardrails / Mimics / Pitfalls
Do not rely on spontaneous GH sampling due to poor reproducibility and overlap with normal responses; avoid in obese patients or those with hypothyroidism where GH secretion may be blunted; do not substitute for IGF‑I screening alone; ensure that provocative testing is performed per guideline 2.3.
Concrete Clinical Example
A 16‑year‑old survivor of acute lymphoblastic leukemia who received 18 Gy cranial radiation presents with decreased growth velocity. The clinician considers ordering a 12‑hour overnight GH profile to evaluate for GHD. Applying the skill, the clinician determines spontaneous GH sampling is not recommended per guideline 2.5 and instead orders an insulin tolerance test with arginine.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-01175